Background—This randomized controlled trial evaluated clinical durability of Zilver PTX, a
paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes …

Background Hemodialysis (HD) access failure is a common cause of increased morbidity
and healthcare cost in patients with end stage renal disease (ESRD). Percutaneous balloon …

A systemic review of published reports on the incidence of early (< 30 days) adverse events
occurring after above-or below-knee femoropopliteal bypass surgery was conducted to …

Background: Drug-eluting technologies improve 12-month angiographic results of
femoropopliteal (FP) interventions, but few data on the comparison between drug-coated …

Objectives: This multicenter, prospective, post-market surveillance study in Japan evaluates
the paclitaxel-coated Zilver PTX stent in real-world patients with complex lesions …

Peripheral artery disease (PAD) is a leading cause of cardiovascular morbidity and mortality
in developed countries, and animal models that reliably reproduce the human disease are …

Objective In recent years, studies of drug-eluting stent (DES) for femoropopliteal artery
diseases (FPADs) have been gradually published. To explore whether this type of stent is …

Objective: Common femoral endarterectomy (CFE) remains the standard of care for
treatment of atherosclerotic stenosis of the common femoral artery (CFA). Endovascular …

Opinion statement Femoropopliteal (FP) disease is a common presentation of peripheral
arterial disease (PAD), and a challenging anatomic region for durable treatment. Surgical …

Objective Atherectomy has become increasingly used as an endovascular treatment of
lower extremity atherosclerotic disease in the United States. However, concerns and …